Thermo Fisher - issue of warrants

Premaitha Health Plc

("Premaitha" or the "Company")

Thermo Fisher - issue of warrants

Manchester, UK - 12 February 2018 - Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, announces that further to the notification made 12 July 2017 it has issued the Second Tranche of warrants to Thermo Fisher Scientific ("Thermo Fisher").

Thermo Fisher has been issued a warrant over 12,417,368 ordinary shares in the Company which may be exercised at a price of 5.775 pence per share, being 10% over the closing share price on 8 February 2018.   In aggregate Thermo Fisher now hold warrants over 95,688,706 ordinary shares, representing 21% of the Company on a fully diluted basis.  The Company has no further contractual commitments to issue warrants to Thermo Fisher.

Following the issue of the warrants above, the Company has warrants over 98,511,560 ordinary shares in issue, including those of Thermo Fisher.  In addition the Company has options over 38,991,232 ordinary shares.

The issued share capital of the Company comprises 321,218,279 Ordinary Shares of 0.1p each.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014 and has been arranged for release by Barry Hextall, Chief Financial Officer of the Company.

-Ends-

About Premaitha

Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group's primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.

Premaitha's IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample - which contains traces of fetal DNA - and estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha's IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia - the world's fastest growing NIPT market - as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.